Lucid Diligence Brief: Sinopia Biosciences receives NIGMS grant for LEADS platform
Lucid Diligence Brief: Sinopia Biosciences receives NIGMS grant for LEADS…
Lucid Diligence Brief: Johnson & Johnson acquires Halda Therapeutics
Lucid Diligence Brief: Johnson & Johnson acquires Halda Therapeutics…
Lucid Diligence Brief: Rectify and Boehringer Ingelheim partnership in CKD
Lucid Diligence Brief: Rectify and Boehringer Ingelheim partnership in CKD…
Lucid Diligence Brief: Surv BioPharma ¥670 million in Series B for primary malignant bone tumors
Lucid Diligence Brief: Surv BioPharma ¥670 million in Series B for primary…
Lucid Diligence Brief: Gilead licenses Assembly Bio’s HSV helicase-primase programs
Lucid Diligence Brief: Gilead licenses Assembly Bio’s HSV helicase-primase…
Lucid Diligence Brief: Vyriad $25M Series B to take in-vivo CAR-T into clinic
Lucid Diligence Brief: Vyriad $25M Series B to take in-vivo CAR-T into clinic…
Lucid Diligence Brief: Sanofi moves to buy Dynavax for $2.2B
Lucid Diligence Brief: Sanofi moves to buy Dynavax for $2.2B Professional…
Lucid Diligence Brief: Neurable raises $35M Series A to scale brain-signal AI
Lucid Diligence Brief: Neurable raises $35M Series A to scale brain-signal AI…
Lucid Diligence Brief: Jacobio and AstraZeneca pan-KRAS asset deal
Lucid Diligence Brief: Jacobio and AstraZeneca pan-KRAS asset deal Professional…
Lucid Diligence Brief: BioMarin to acquire Amicus Therapeutics for $4.8B
Lucid Diligence Brief: BioMarin to acquire Amicus Therapeutics for $4.8B…
Lucid Diligence Brief: Syremis Therapeutics launches with $165M Series A in schizophrenia
Lucid Diligence Brief: Syremis Therapeutics launches with $165M Series A in…
Lucid Diligence Brief: BioNTech completes acquisition of CureVac
Lucid Diligence Brief: BioNTech completes acquisition of CureVac Professional…